Market activity in after-hours trading showed distinct winners and losers as corporate earnings and forward guidance hit investor screens.
Intel (INTC) was the standout mover. The company reported second-quarter adjusted earnings per share of $0.42, roughly double the Wall Street estimate of $0.21, on revenue of $16.13 billion. Management said it expects the momentum to carry into the third quarter and guided revenue to a range of $15.8 billion to $16.8 billion, above a $15.1 billion consensus figure. Executives attributed the outlook to accelerating AI-driven compute demand spanning Intel's CPU and foundry franchises. The outsized beat and upward-leaning guidance drove a roughly 12% rise in the stock in after-hours trade and also buoyed rival chip names, with investors interpreting the report as evidence of strengthening PC and server chip demand.
MaxLinear (MXL) moved in the opposite direction despite posting a quarter that topped estimates and supplying robust guidance for the upcoming period. The company forecast third-quarter revenue of $210 million to $220 million, notably above the $173.8 million consensus. Even so, MaxLinear shares fell about 7% after markets closed. The sell-off followed an extended rally in the stock ahead of results; traders appeared to take profits after a period of rapid appreciation tied in part to enthusiasm for the company’s 800G optical data center platform.
Deckers Brands (DECK) also saw a downward after-hours move, sliding roughly 3% following a modest fiscal first-quarter beat. The company reported earnings per share of $0.94 on revenue of $1.02 billion. For full-year fiscal 2027, Deckers maintained a cautious outlook, guiding EPS to $7.35 to $7.50 with revenues up to $5.91 billion, a range that matched analysts’ expectations. With no material "beat-and-raise" outcome and only confirmed guidance, investors reacted cautiously, even as the HOKA brand continued to show strength.
Edwards Lifesciences (EW) was among the after-hours gainers, rising about 6% after a solid second quarter. The medical device maker posted adjusted EPS of $0.78 on $1.74 billion in revenue, topping forecasts. Edwards reaffirmed its full-year EPS range of $2.95 to $3.05 and issued third-quarter EPS targets of $0.71 to $0.77. Management cited steady procedure growth in transcatheter aortic valve replacement, or TAVR, as a supporting factor for its outlook and for investor confidence.
Taken together, the results underscore divergent investor responses to beats and guidance across sectors: semiconductors experienced both a clear positive catalyst in Intel's report and profit-taking in other names, while apparel and medical device companies produced measured reactions tied to conservative or reaffirmed outlooks.